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We examined whole-genome–sequenced Campylobacter 
jejuni/ and C. coli from 2012–2015 isolated from birds and 
human stool samples in North East Scotland for the pres-
ence of antimicrobial resistance genes. We found that se-
quence type (ST) 5136 (clonal complex 464) was the most 
prevalent multidrug-resistant strain of C. jejuni exclusively 
associated with poultry host reservoirs and recovered from 
human cases of campylobacteriosis. Tetracycline resis-
tance in ST5136 isolates was due to a tet(O/32/O) mosaic 
gene, ampicillin resistance was conferred by G →T trans-
version in the –10 promoter region of blaOXA-193, fluoroqui-
nolone resistance was due to C257T change in gyrA, and 
aminoglycoside resistance was conferred by aac. Whole-
genome analysis showed that the strain ST5136 evolved 
from ST464. The nationwide emergence of ST5136 was 
probably due to stepwise acquisition of antimicrobial resis-
tance genes selected by high use of β-lactam, tetracycline, 
fluoroquinolone, and aminoglycoside classes of drugs in 
the poultry industry.
Campylobacter jejuni and C. coli are the most common causes of bacterial foodborne gastroenteritis in the in-
dustrialized world (1). In the United Kingdom alone, Cam-
pylobacter is implicated in >500,000 cases, 80,000 medi-
cal consultations, and 200 deaths and costs the economy 
an estimated £1 billion annually (2,3). According to World 
Health Organization estimates, Campylobacter-related 
sequelae affect ≈1% of the worldwide population (4). In 
the United Kingdom, human infection has been associated 
with retail chicken meat products (55%–75% attribution); 
cattle and sheep have a secondary role and wild birds, pigs, 
and dogs minor roles (5–7). Most human Campylobacter 
infections are mild and self-limiting and resolve within a 
few days, but severe or prolonged infections can occur, par-
ticularly in the young, elderly, and immunocompromised 
patients with AIDS or other vulnerable categories for which 
therapeutic intervention may be warranted (8).
For clinical therapy of campylobacteriosis, antimicro-
bial drugs, such as erythromycin, are usually prescribed, 
but ciprofloxacin is advised in moderately severe cases of 
nonconfirmed gastroenteritis and for travelers’ diarrhea (9). 
In recent years, treatment with fluoroquinolones has been 
challenging because of an increasing prevalence of fluoro-
quinolone resistance in human Campylobacter isolates that 
led to the ban of the fluoroquinolone enrofloxacin for use in 
poultry in the United States in 2004 (10).
The Veterinary Medicines Directorate reports that in 
2016 a total of 337 tons (17% decrease from 2015) of autho-
rized veterinary antimicrobial drugs were sold in the Unit-
ed Kingdom. The sales of trimethoprim, sulphonamides, 
β-lactams, and aminoglycosides remained stable between 
2012 and 2016, but notable reductions were observed for 
tetracycline (30%), macrolides (24%), and fluoroquino-
lones (29%) from 2015 to 2016 (11). Only enrofloxacin and 
difloxacin are licensed for poultry use; 0.5 metric tons of 
active ingredient were sold for use in poultry production in 
2015 to the British Poultry Council, a national trade group 
that accounts for 90% of all broilers produced in the United 
Kingdom (12).
The main drivers for the acquisition of antimicrobial 
resistance (AMR) are selection pressure and the opportu-
nity for horizontal gene transfer (13). Multidrug resistance 
has been defined as resistance to >3 classes of antimicro-
bial drugs and can occur by stepwise mutation or single 
plasmid acquisition of AMR genes (14,15). A report com-
missioned by the UK Food Standards Agency shows that 
drug-resistant Campylobacter species are becoming more 
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prevalent; evidence shows increasing levels of resistance 
in bacteria from poultry meat (16), which makes up around 
half of all meat by weight purchased in the United King-
dom (33 kg/person) (17).
The aim of this study was to establish the evolutionary 
course of events that led to the emergence of a multidrug-
resistant (MDR) organism by considering the interplay 
between selection pressures and genetic changes. Specifi-
cally, we investigated whether antimicrobial resistance to 
β-lactams, tetracyclines, fluoroquinolones, and aminogly-
cosides in the ancestral lineages of C. jejuni ST5136 (Fig-
ure 1) led to the emergence of a strain that is the causative 
agent of human campylobacteriosis in 1 of 20 cases in the 
United Kingdom (18).
Materials and Methods
Bacterial Isolates and Genotyping
Campylobacter isolates for this study came from patients 
who had campylobacteriosis during 2012–2015 and from 
chicken and turkey retail meat samples. We incubated the 
meat samples at ambient temperature in enrichment broth 
for 1 h with occasional agitation and plated 100 μL of 
the broth on mCCDA plates (E & O Laboratories, http://
www.eolabs.com). We then incubated the plates under 
microaerobic conditions at 37ºC for 48 h and extracted 
genomic DNA using the Wizard Genomic DNA Purifica-
tion Kit (Promega, https://www.promega.com). Whole-
genome sequencing was performed using HiSeq 2000 
sequencer (Illumina, https://www.illumina.com) with 100 
bped-end sequencing. We assembled FASTQ paired-end 
reads using Velvet (19) with a typical 50× coverage and 
assembled genome size of ≈1.6 Mbp. We uploaded the 
genomes to the Bacterial Isolate Genome Sequence Data-
base (BIGSdb) and typed them using the 7-locus multilo-
cus sequence typing (MLST) and whole-genome MLST 
(wgMLST) schemes (20,21).
Antimicrobial Resistance Gene Determinants
We assessed AMRs in silico for clonal complexes (CC) 
464 (parent CC of ST5136), CC353, CC354, and CC574 
(n = 494, North East Scotland; n = 68, England). We 
determined the tetracycline resistance (CAMP1698) and 
bla
OXA-61
–like (CAMP0265) variants in accordance with 
BIGSdb (20). We assessed the flanking sequence of 
bla
OXA-61
–like for the G → T transversion in the –10 pro-
moter region by exporting 100 bp flanking allele sequenc-
es in XMFA/concatenated FASTA formats from C. jejuni/ 
coli PubMLST isolate database (22). We also screened 
isolates for gyrA and 23S rRNA V domain mutations, 
bla
OXA-184
–like and presence of ermA, emrB, ermC, and 
ermF using BIGSdb and Resfams (23,24). We identi-
fied putative aminoglycoside resistance genes encoding 
N-acetyltransferases (AAC), O-adenyltransferases (ANT), 
O-phosphotransferases (APH), and streptothricin acetyl-
transferase (SAT) using Resfams (25).
Genome Annotation and Phylogenetic Analyses
We chose 100 isolates with 1 C. coli (CC828) outgroup that 
were representative of the closely related clonal complexes 
CC464, CC353, CC354, and CC574 from BIGSdb. The group 
consisted of isolates from North East Scotland (n = 31), Eng-
land (n = 68), and Estonia (n = 1). We annotated their genomes 
using RAST (26) and analyzed them by whole-genome mul-
tilocus sequence typing (wgMLST) using 1,643 Gundogdu 
loci (27). We constructed a phylogenetic tree in Bionumerics 
v. 7.6 (Applied Maths, http://www.applied-maths.com) us-
ing the topscore unweighted pair group method with arith-
metic mean algorithm based on similarity of wgMLST loci. 
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Figure 1. Stepwise sequential evolution of multidrug resistance 
in Campylobacter jejuni ST5136, Scotland. Red dots indicate 
resistance to antimicrobial drug as a result of genetic change or 
acquisition of resistance gene; white dot with red outline  
indicates acquisition of oxacillinase. Resistances are indicated 
as follows: aac3, aminoglycoside; C257T gyrA, fluoroquinolone; 
blaOXA-61–like, β-lactam (variant in ST5136 is OXA-193); 
tet(O/32/O), tetracycline. CC, clonal complex; OXA, oxacillin;  
R, resistant; ST, sequence type.
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We constructed maximum-likelihood trees for aminoglyco-
side resistance determinants in MEGA7 (28).
Antimicrobial Susceptibility Testing and Strain Stability
We determined antimicrobial susceptibility for 21 represen-
tative CC464 isolates with genotypic polymorphisms across 
the range of detected resistance markers. We used Mueller-
Hinton agar with 5% defibrinated horse blood and 20 mg/L 
β-nicotinamide adenine dinucleotide for antimicrobial sus-
ceptibility testing using the disk diffusion method for cip-
rofloxacin (5 μg/disk), gentamicin (10 μg/disk), tetracycline 
(5 μg/disk), kanamycin (5 μg/disk), amikacin (30 μg/disk), 
tobramycin (10 μg/diskc), and streptomycin (30 μg/disk) 
(29,30). We determined MIC of ampicillin (AMP) by Etest 
(Oxoid, http://www.oxoid.com) and interpreted the MICAMP 
and disk susceptibility results using guidelines from the Eu-
ropean Committee on Antimicrobial Susceptibility Testing 
and Clinical and Laboratory Standards Institute and inter-
preted them as described previously (29). We used the an-
timicrobial drug–susceptible isolate ARI3025 as a control. 
We subcultured the ST5136 isolate ARI4158 on antibiotic-
free blood agar plate (ARI4158_20) 22 times to assess the 
stability of its antimicrobial resistance genes.
Statistical Analyses
We calculated 95% CIs by 10,000 bootstrap iterations 
to assess if there were significant differences in clonal 
complexes or individual strains with respect to resistance to 
different antimicrobial drug categories or AMR resistance 
alleles. If the CIs did not overlap (e.g., between 2 groups 
for a particular factor), then we inferred the comparison to 
be statistically significant (p<0.05).
Results
Genomic Analyses of Resistance in CC464,  
CC353, CC354, and CC574
We compiled the metadata of 494 isolates from North 
East Scotland, including strain types and resistance geno-
types (Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/25/7/18-1572-App1.xlsx). This list includes the an-
timicrobial resistance genotype of isolates in CC464 (n = 
229), CC353 (n = 116), CC354 (n = 113), and CC574 (n 
= 36) from across the United Kingdom. Of these, 97% of 
CC464 isolates were MDR, followed by 95% of CC354 
and 67% of CC574; CC353 (38%) showed lower levels of 
antimicrobial resistance. Multidrug resistance in CC464 
was significantly higher (p<0.05) than that for the other 
clonal complexes. All ST5136 isolates had genes or mu-
tations conferring resistance to tetracycline, ciprofloxacin 
(all isolates except 1), and ampicillin. We observed >1 
aminoglycoside resistance gene (aac3 variants in ST5136 
isolates with 75% (n = 8) showing phenotypic resistance to 
kanamycin (Table 1; Figure 2).
We detected macrolide resistance in ARI2246 (ST2036, 
CC353), ARI2515 (ST3155, CC354), and ARI3316 (ST2438, 
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Table. Phenotypic evaluation of antimicrobial drug–resistant genotypes of Campylobacter jejuni ST5136 CC464 isolates, Scotland* 
pubMLST 
ID Isolate Year Source 
gyrA 
C257T CIP OXA† AMP tet variant‡ TET 
aac3 
variant KAN TOB 
38459 ARI1530 2012 Human stool T R A S tet(O)80 R G1 R S 
39121 ARI2250 2013 Human stool T R A S A S G1, G4 R S 
41320 ARI3377 2014 Human stool T R OXA-465 R tet(O/32/O)7 R G1 R S 
40661 ARI3044 2013 Human stool T R A S tet(O/M/O)218 R G1 R S 
38785 ARI1899 2012 Human stool T R A S tet(O)13 R G1 R R 
38883 ARI2002_1 2012 Human stool T R OXA-193 (G) S tet(O/32/O)7 R G1 R S 
39844 C0525 2013 Turkey T R OXA-193 (T) R tet(O/32/O)7 R G1 R S 
42202 C1204 2014 Chicken T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 R R 
40371 ARI2986 2013 Human stool T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 I S 
48290 ARI4158 2015 Human stool T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 I S 
42443 C1522 2015 Chicken T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 R S 
58497 C0112 2010 Chicken T R OXA-193 (T) R tet(O/32/O)7 R G1 R S 
58473 ARI0533 2010 Human stool T R OXA-193 (T) R tet(O/32/O)7 R G1 R S 
41611 C0972 2014 Chicken T R OXA-193 (T) R tet(O/32/O)7 R G2 I S 
39810 C0469 2012 Turkey T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 R S 
58159 ARI3975 2015 Human stool C S OXA-193 (T) R tet(O/32/O)7 R G1, G4 R S 
39411 ARI2623 2013 Human stool C S OXA-193 (T) R A S G1 R R 
38522 ARI1599 2012 Human stool T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 R R 
38475 ARI1546 2012 Human stool T R A S tet(O/32/O)7 R G1 R R 
48369 ARI3988 2015 Human stool T R A S tet(O/32/O)7 R G1 R S 
42114 ARI3830 2015 Human stool C S OXA-193 (T) R tet(O/32/O)7 R G1, G4 R R 
48290 ARI4158_20 2015 Human stool T R OXA-193 (T) R tet(O/32/O)7 R G1, G4 I S 
*Result based on disk susceptibility testing, except for ampicillin, for which MIC was estimated. R indicates MIC >128mg/L. All isolates were sensitive to 
amikacin, gentamicin, and streptomycin. aac3, 3-N-aminoglycoside acetyltransferase gene groups (G1–G4); AMP, ampicillin; CC, clonal complex; CIP, 
ciprofloxacin; I, intermediate; ID, identification; KAN, kanamycin; R, resistant; S, sensitive; ST, sequence type as determined by multilocus sequence 
typing; TET, tetracycline; TOB, tobramycin. 
†OXA-465 = blaOXA-184-like gene; A indicates absence of oxacillinase gene; (G) or (T) indicates guanine or thymine mutation at 10 promoter of blaOXA-193. 
‡A indicates absence of tetracycline resistance gene. 
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CC354), all of which had A2075G mutation in the 23S rRNA 
V domain, observed by erythromycin disk diffusion assay. We 
found no mutations at 2074 and observed no resistance due 
to erm (erythromycin ribosome methylation) genes in any of 
the isolates.
Fluoroquinolone resistance determined by the gyrA 
(CAMP0950) C257T mutation was significantly higher in 
CC464 (226/229, 99%), the parent clonal complex of ST5136; 
CC353 (77/116, 66%); and CC354 (107/113, 95%) isolates, 
compared with CC574 (8/36, 22%) (p<0.05) (Figure 2; 
Appendix Table 1). β-lactam resistance was conferred primarily 
by the bla
OXA-61
–like (CAMP0265). CAMP0265 allele 1 and 14 
encoded the OXA-193 enzyme occurring in CC464, CC353, 
and CC574 isolates, whereas CAMP0265 allele 38 (OXA-
460) was significantly associated with CC354 group of iso-
lates (p<0.05). ARI3377 (ST464) and ARI2874 (ST581) had 
bla
OXA-184
–like and lacked any bla
OXA-61
–like genes. CC353 
isolates had relatively lower prevalence (19/113, 17%) of oxa-
cillinase. Resistance to β-lactams as a result of a –10 promoter 
mutation upstream of the bla
OXA-61
–like or the presence of 
bla
OXA-184
–like was significantly greater in CC464 (217/229, 
95%) and CC354 (79/113, 70%) compared with CC353 
(11/116, 9%; p<0.05), whereas 21/36 (58%) of CC574 iso-
lates were found to be resistant to β-lactams (p>0.05) (Ap-
pendix Table 1). Amino acid sequence identity revealed that 
OXA-193 (257 aa) and OXA-460 (253 aa) are 97.7% similar, 
which may be the result of environmental conditions or eco-
logic adaptations as listed previously (31,32).
Tetracycline resistance was significantly higher in 
CC464 (221/229, 97%), CC354 (108/113, 96%), and 
CC574 (29/36, 81%) than in CC353 (43/116, 37%; p<0.05) 
(Appendix Table 1). The mosaic tet(O/32/O)7 was sig-
nificantly associated with CC464, whereas the tet(O)8 
and tet(O)10 were associated with CC354 and CC574 
(p<0.05) (Figure 2). Of CC464 isolates, 93% (214/229) 
had the chromosomal tet(O/32/O)7–like disrupting dcuC 
(CAMP1639). Two ST464 clinical isolates, ARI3458 and 
OXC6581, were positive for both tet(O/32/O)7 and tet(O). 
In ARI3458, tet(O/32/O)7 was chromosomal and tet(O) 
was plasmidborne, but the location could not be deter-
mined in OXC6581 (Figure 3; Appendix Table 2). We 
observed that tet(O/32/O) alleles 7 and 22 and tet(O)10 oc-
curred very rarely in CC353 isolates. We found the mo-
saic tet(O/32/O)7–like determinants on either plasmid or 
chromosome in CC353, CC354, CC574, and other clonal 
complexes but at a much lower frequency (Appendix Ta-
ble 2). The CAMP1698_10 variant occurred in OXC8770, 
ARI1655, and ARI3389 (ST3015, CC574) and had 98.7% 
similarity (631/639) to Streptococcus phage_phi-m46.1 
tet(O) sequence FM864213.1.
The Resfams database identified aminoglycoside re-
sistance determinants with lengths ranging from 96–263 
aa. We did not assign allele numbers to determinants with 
polypeptide lengths of 96–169 aa and deemed them pseu-
dogenes, whereas those with length >261 aa we identi-
fied as novel putative aminoglycoside resistance genes 
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Figure 2. Whole-genome phylogenetic tree of Campylobacter jejuni CC464, CC353, CC574, and CC354 isolates, Scotland; 
a indicates CC464 root and b indicates CC464 isolates excluding ST5136. β-lactamase gene (blaOXA-61–like) indicates presence of 
abundant allele and other OXA genes; β-lactamR, resistant isolates (defined by -10 promoter mutation or presence of OXA-184–like 
gene). tet gene indicates presence of abundant tetracycline resistance allele and other alleles; TetR, tetracycline-resistant isolates. 
AG allele indicates presence of abundant aminoglycoside allele and other alleles in a group of strains associated at the CC level; 
other indicates any other aac3 resistance allele or a combination of the abundant allele along with a second aac3; AGR indicates  
aminoglycoside-resistant isolates. FQ allele indicates most abundant gyrA allele and other alleles that confer fluoroquinolone resistance; 
FQR indicates fluoroquinolone-resistant isolates. MDR is defined as resistance to >3 antimicrobial drugs. CC, clonal complex; MDR, 
multidrug resistant; OXA, oxacillin; R, resistant; ST, sequence type.
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Figure 3. Whole-genome multilocus 
sequence typing of 100 selected 
isolates of Campylobacter jejuni 
from CC464, CC353, CC354, and 
CC574, Scotland. The tree was 
constructed using the UPGMA 
algorithm based on locus similarity. 
Isolate ID number indicated at 
branch end is linked to metadata in 
Appendix Table 2 (https://wwwnc.cdc.
gov/EID/article/25/7/18-1572-App1.
xlsx). Light orange boxes in the grid 
indicate variants associated with 
ST5136 isolates spread across the 
phylogeny; dark orange boxes denote 
resistance in individual isolates. 
Blue boxes represent tetracycline 
resistance in chromosome; 
yellow boxes, in plasmid. AG, 
aminoglycoside; CC, clonal complex; 
ID, identification; OXA, oxacillin; ST, 
sequence type; TET, tetracycline.
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after BLAST query (Figure 4; Appendix Tables 1, 2). We 
identified a total of 17 aac3 (groups G1–G4), 1 aph (O-
phosphotransferase), and 1 ant aminoglycoside resistant 
gene. We grouped the aac3 allelic variants as v7, v15, 
v17, v24–28, (G1); v8, v10, v29 (G2); v19 (G3); and 
v11, v22, v30–32 (G4) (Figure 4). We identified >1 aac3 
variant in all isolates and no aac6′ enzymes. We identi-
fied streptothricin acetyltransferase (SAT_4), aph (v2), 
aph3′-IIIa (v1), and O-adenyltransferase (aadE/ant6, 
v2) in a single isolate of C. jejuni (ARI2517, ST2140/
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 7, July 2019 1325
Figure 4. Maximum-likelihood 
tree of all aminoglycoside 
resistance determinants found 
in Campylobacter jejuni CC464, 
CC353, CC354, and CC574 
isolates, Scotland. The tree 
was built using MEGA7 (https://
www.megasoftware.net). The 
variants (v) listed in G1, G2, G3, 
G4 groups commonly occur in 
the 4 CCs. Scale bar indicates 
nucleotide substitutionsj per site. 
Aminoglycoside resistance gene 
variants identified in representative 
isolates of 4 CCs are shown by 
different symbols: black diamonds, 
aac3; black squares, aph; black 
triangles, ant; black circle, sat. CC, 
clonal complex.
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CC574). We identified the aadE/ant6, v2 in ARI2168 
(ST400/CC353) also, and aadB in ARI1990 (ST2116/
CC353) (Appendix Table 1). All CC464 isolates were 
positive for >1 aac3 gene (Figure 2; Appendix Table 1, 
2). The aac3 allele v17 was significantly more common in 
CC464 compared with v8 and v22 that occurred in other 
clonal complexes (Figure 2).
Antimicrobial Susceptibility Testing and Strain Stability
We performed susceptibility testing and corroborated 21 
isolates of CC464 with genotypes predictive of resistant 
or sensitive phenotypes for different antimicrobial drugs 
(Table). Past studies show that disk diffusion correlated 
well to MIC determination and reliably distinguished 
between sensitive, intermediate, and resistant isolates 
of Campylobacter (33); hence, we used this method to 
assess and interpret genotypic data linked to isolate phe-
notype. Previous research has observed that the C257T 
gyrA genotype conferred ciprofloxacin resistance, G57T 
change in the -10 promoter of bla
OXA-61
-like led to an in-
crease in ampicillin resistance, and all tetracycline resis-
tance genes conferred resistance to tetracycline (Table) 
(22,34,35). We observed resistance to kanamycin in 
18/21 aac3-positive isolates harboring alleles v22 and 
v17, indicating that these variants may have the ability 
to hydrolyze kanamycin (Table); this finding warrants 
further investigation. Most of the isolates displayed a 
tobramycin-sensitive phenotype, whereas all were sensi-
tive to amikacin, streptomycin, and gentamicin (Table). 
We subcultured isolate ARI4158 (ST5136) 22 times on 
antibiotic-free blood agar to assess the stability of its 
antimicrobial resistance genes, but we found it to be re-
sistant like the parent isolate.
Phylogenetic Relationships
We constructed a phylogeny of 100 representative iso-
lates of CC464 and associated clonal complexes us-
ing 1,643 wgMLST loci (Figure 3; Appendix Table 
2). As predicted, ST5136 clustered within CC464; 
CC353, CC354, and CC574 isolates clustered, in that 
order, distal to CC464. ST5136 isolates were a single 
clonal MDR group closely related to the MDR isolates 
of ST5812 (CC464) reported in Guernsey in 2012 and 
now also found in England and Scotland (Figure 3). We 
observed the clustering of CC353, CC354, and CC574 
around CC464 at the wgMLST level at which CC353 
and CC354 strains had a high prevalence of ciprofloxa-
cin resistance, whereas CC574 had a lower prevalence of 
ciprofloxacin resistance. Our findings concur with those 
reported earlier (36). Strain ST6209 (isolate no. 72, re-
sistant only to β-lactam) clustered around ST464 isolates 
(nos. 73, 74, 75) that had genotypes encoding low levels 
of resistance (Figure 3).
Discussion
The UK broiler sector is the fourth-largest poultry meat pro-
ducer in the European Union, making the United Kingdom 
≈75% self-sufficient in poultry meat. The industry has ben-
efited from the continuing consumer choice of leaner meat, 
reflected in the 12% rise in poultry meat sales in 2017. The 
widespread presence of antimicrobial resistance in Campy-
lobacter spp. in retail poultry in the United Kingdom sug-
gests horizontal transfer and mutational events within and 
between broiler farms and environmental conditions lead-
ing to proliferation of antibiotic-resistant lineages (37,38). 
This process is observed in ST5136, which was first detect-
ed in 2010 as an ST464 variant isolated from chicken meat 
(C0112) and clinical stool samples (ARI0509) from North 
East Scotland and Oxford (OXC5459). In 2012, ST5136 
was reported from turkey meat (C0469) in North East Scot-
land, and in all cases from both years these isolates were 
MDR. ST5136 was never detected before 2010 in any of 
the 15,365 isolates submitted to the PubMLST Campylo-
bacter database, but since its discovery, it has been found 
in >18 abattoirs across the United Kingdom. ST5136 has 
only ever been isolated from poultry (chicken 90%, turkey 
10%, duck <1%) and never from cattle, sheep, pigs, or wild 
birds (39). Thus, human acquisition is probably exclusively 
from poultry meat.
The evolutionary ancestry of ST5136 shows that it is 
a member of CC464 and evolved from a heterogeneous 
complex of related strains, including ST464, all of which 
show high prevalence of antimicrobial resistance (Figure 
3). ST5136 forms a cluster within CC464, an ancestor of 
CC353 with CC574 and CC354 associated more distally 
(Figure 2).
In the PubMLST Campylobacter database, the earliest 
report of ST354 was from a human blood culture in 1984; 
in 1991 it was isolated from chicken meat in the United 
Kingdom (39). ST574 was isolated in Thailand in 1999 and 
reported in the United Kingdom from an unspecified human 
sample in 2000 and chicken meat in 2001 (39). The clos-
est ancestor of ST464 is ST353, which was isolated from 
chicken in 1982 in the United Kingdom, and ST464, re-
ported in 2001 from chicken meat in Northern Ireland (first 
report of ST464 was from Germany in 2000 from human 
stool) and then ST5136 reported in 2010 (39). We com-
piled an illustration of the acquisition of resistance markers 
in ST5136 from ST464 (Figure 1). In the ancestral state, 
most CC464 isolates harbor aac3 and then acquire cipro-
floxacin resistance, tet(O/32/O) and bla
OXA-61
-like. Subse-
quently, a mutation in the bla
OXA-61
-like promoter leads to 
very high levels of ampicillin resistance. All these events 
have led to the stepwise selection of increasing drug resis-
tance phenotypes in an intensely antimicrobial-competitive 
environment (Appendix Table 2). Ancestral to CC464 is 
CC353 and somewhat more distally CC574 and CC354, 
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each of which shows progressively lower proportions of 
antimicrobial-resistant isolates. The commonality of the 
alleles for genes conferring resistance to the 4 different 
classes of antimicrobial drugs examined in this article in-
dicates a gradual accumulation of these markers, culminat-
ing in ST5136. The most recently observed marker, gyrA57, 
is common to isolates of ST5136 and its cogenitor CC464 
and leads to ciprofloxacin resistance, resulting in resistant 
strains that are related and are fitter than their sensitive 
counterparts (Figure 2; Appendix Table 2) (34). Because 
most ST5136 isolates show high levels of fluoroquinolone, 
β-lactam, aminoglycoside, and tetracycline resistance, it is 
likely that these related isolates evolved from a resistant 
ST464 ancestor.
The tet(O/32/O)7 and aac317 alleles were most likely 
acquired previously, before the divergence of CC464 from 
CC353. Purifying selection of resistances could be occur-
ring in CC464, as tet(O/32/O)7 in this group was increas-
ingly common compared with the ancestral strains. The 
tetracycline resistance gene tet(O/32/O)7 is found on ei-
ther plasmids or the chromosome in the ancestral isolates 
CC464, CC353, CC354, and CC574, but by the appearance 
of the CC464 ancestor of ST5136, it is found only on the 
chromosome, suggesting acquisition either via conjuga-
tion or by transformation into the last common ancestor. 
There is a constant flow of resistance genes between plas-
mids, phages, and bacteria in the farm environment and the 
chicken gut microbiome. Species such as Streptococcus 
and Enterococcus that form a part of the chicken gut micro-
biome often harbor promiscuous plasmids with resistance 
genes that can occur in Campylobacter; this exchange of 
genetic determinants will be a contributor to antimicro-
bial resistance evolution in Campylobacter (40,41). Simi-
larly, OXA-193 dominated in isolates of CC464 that were 
closely ancestral to ST5136 and evolved to be more highly 
resistant to β-lactam antimicrobial drugs as a result of the 
–10 promoter mutation in the upstream region of bla
OXA-193
.
Superimposed onto this linear phylogeny of antimicro-
bial resistance in ST5136 are the genetic changes occur-
ring in the other strains of the related lineages (Figure 1). 
In Campylobacter the principal sources of genetic change 
are intracellular mutational events and the acquisition of 
extracellular genes from other isolates; these events are es-
timated as equally common (34,42), mutations resulting in 
a clonal distribution of characters in related isolates and the 
acquisitions in a mosaic distribution of characters across 
the species. These sources of genetic diversity lead to the 
emergence of novel variants in fitter isolates selected by the 
environment. Thus, for Campylobacter, there is a complex 
distribution of individual genetic markers when viewed 
in the context of the overall phylogeny of related isolates. 
This finding is most clearly exemplified in the example of 
1 ST5136 isolate (ARI3975), which has a basal level of 
resistance to ampicillin and no promotor mutation; these 
aspects could be the result of a spontaneous back muta-
tion or horizontal gene transfer from a sensitive strain of 
Campylobacter.
Resistances are propagated across the clonal popula-
tion of Campylobacter; from these survival-of-the-fittest 
chains of events in antimicrobial drug–rich environments, 
such as poultry farms, may emerge more abundant lineages 
due to the prophylactic or metaphylactic use of drugs (43). 
ST464 has given rise to 2 MDR strains: ST5136 (uncA 
allele 1→3) and ST5812 (pgm allele 10→17), which are 
closely associated with each other. It is unclear whether 
the spread of ST5136 was better facilitated than that of 
ST5812 or that other genetic changes in ST5136 made it 
more likely than ST5812 to survive and colonize in poultry 
or by chance.
Dissemination of highly related Campylobacter strains 
throughout the poultry industry has occurred previously. 
In New Zealand, C. jejuni ST474 (CC48) was a dominant 
strain found almost exclusively in isolates from 1 poultry 
supplier and associated with clinical cases during 2005–
2008 (44). More recently, tetracycline- and fluoroquino-
lone-resistant C. jejuni ST6944 (CC354, one of the ances-
tors of CC464) has been reported in human cases and in 3 
major poultry suppliers in New Zealand (45).
The UK poultry industry has responded well to the 
current BPC antibiotic stewardship program with a 71% 
reduction in use of antimicrobial drugs from 2012 to 2016, 
but it is worth noting that enrofloxacin and difloxacin are 
authorized fluoroquinolones currently used in the chicken 
industry in the United Kingdom (46). A 1991 study in the 
Netherlands reported an increase in fluoroquinolone re-
sistance in Campylobacter correlated with increasing use 
of enrofloxacin in the poultry industry and thus the trans-
mission of fluoroquinolone-resistant Campylobacter from 
chickens to humans (38). In 2012, the poultry industry 
phased out use of the modern cephalosporins completely, 
but a commitment to stop the prophylactic use of fluoro-
quinolones in day-old chickens was not made until 2016 
(46). Even then, these antimicrobial drugs may be added to 
the drinking water of flocks of poultry when no disease is 
present in most of the birds in a flock (47). The continued 
occurrence of resistant strains that emerge in an antimicro-
bial-stressed environment but retain their resistance in en-
vironments even after the cessation of antibiotic pressure 
has been reported previously (48). Although positive anti-
microbial usage may mitigate against the creation of future 
MDR bacteria, preexisting MDR strains, such as C. jejuni 
ST5136, may never lose their resistance characteristics.
Joshua Lederberg has said, “The future of human-
ity and microbes likely will unfold as episodes of Our 
Wits Versus Their Genes” (49). The evolution and rise 
of ST5136 indicates that bacteria can evolve by genetic 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 25, No. 7, July 2019 1327
RESEARCH
adaptation to antibiotic-enriched and -deprived environ-
ments, which drives the evolution of environment-favored 
strains by mutation or gene transfer. It is up to us to use 
our wits to keep up with these changes.
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